Digestive Endoscopy Unit, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano (Milano), Italy.
Surg Endosc. 2013 Jul;27(7):2487-91. doi: 10.1007/s00464-012-2762-x. Epub 2013 Feb 27.
Benign colorectal strictures are treated conventionally by endoscopic dilation. Experience using SEMS for benign colonic strictures is limited, and outcomes to date have been disappointing. Refractory colorectal strictures remain challenging to be treated with surgery. Polydioxanone-based stent are biodegradable (BD) stent CE approved for esophageal strictures. This study was designed to investigate retrospectively the safety and the efficacy of these stents for the management of strictures refractory to multiple sessions of dilation.
Patients with postsurgical benign strictures located within 20 cm from anal verge, refractory to mechanical or pneumatic dilation (at least 3 sessions) were included in this analysis. Clinical success was defined as the absence of occlusive symptoms and the ability to pass through the stricture with a regular size colonoscope. All patients were predilated before stent placement. Stents were released under fluoroscopic control. All patients were under stool softeners for 3 months. Follow-up was scheduled with endoscopic and fluoroscopic controls within 90 days from stent deployment and afterwards by telephone interview and/or ambulatory consultation.
Eleven patients (7 males, mean age 62.3 ± 8.5 years) were included. Technical success was achieved in all the patients. Stent migration was observed in four patients within the first 2 weeks after stent placement. Stent migration was followed by recurrence of stricture and obstructive symptoms in all the cases. Among the seven patients who completed the process of stent biodegradation, five of them had complete resolution of the stricture and relief of symptoms. Two of 11 patients required surgical treatment during the follow-up period (mean 19.8 (range 42-15) months). The overall success rate of the BD stent was 45 %.
This retrospective analysis of a limited number of patients demonstrated that nondedicated esophageal BD stents are associated with high risk of migration and clinical success in less than 50 % of patients. Dedicated stents with large diameter and antimigration findings could potentially improve the outcome of patients with refractory benign colorectal strictures.
良性结直肠狭窄通常通过内镜扩张治疗。使用 SEMS 治疗良性结肠狭窄的经验有限,迄今为止的结果令人失望。复发性结直肠狭窄仍然是手术治疗的挑战。基于聚二氧杂环已酮的支架是可生物降解的(BD)支架,已获得 CE 批准用于治疗食管狭窄。本研究旨在回顾性研究这些支架治疗对多次扩张治疗抵抗的狭窄的安全性和疗效。
本分析纳入了位于肛门 20cm 以内的术后良性狭窄且对机械或气动扩张(至少 3 次)有抵抗的患者。临床成功定义为无阻塞症状和能够通过常规尺寸的结肠镜通过狭窄。所有患者在支架放置前均进行预扩张。在荧光透视控制下释放支架。所有患者均在 3 个月内服用大便软化剂。支架放置后 90 天内进行内镜和荧光透视随访,之后通过电话访谈和/或门诊咨询进行随访。
共纳入 11 例患者(7 例男性,平均年龄 62.3 ± 8.5 岁)。所有患者均获得技术成功。支架迁移发生在支架放置后 2 周内的 4 例患者中。支架迁移后,所有病例均出现狭窄和阻塞症状复发。在完成支架生物降解过程的 7 例患者中,5 例患者的狭窄完全缓解,症状缓解。11 例患者中有 2 例在随访期间需要手术治疗(平均随访时间 19.8 个月,范围为 42-15 个月)。BD 支架的总体成功率为 45%。
这项对有限数量患者的回顾性分析表明,非专用食管 BD 支架迁移风险高,临床成功率不足 50%。具有大直径和抗迁移特性的专用支架可能会改善复发性良性结直肠狭窄患者的预后。